spacer
home > directory > CMAB Biopharma
PHARMACEUTICAL INDUSTRY DIRECTORY

CMAB Biopharma

CMAB Biopharma
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.

Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.

Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 165 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.

At CMAB biopharma, we provide expertise and experience in process and analytical development, drug substance (DS) and drug product (DP) cGMP manufacturing. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer, which is used for protein characterisation. Our four parallel upstream suites offer flexible cGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. CMAB is currently installing a fully automated aseptic fill / finish line along with a lyophiliser, which will be capable of producing commercial quantities of DP in early 2020. Finally, we can also provide our clients with lot release testing and stability studies.

Our operational protocols and quality standards comply with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce cGMP material for global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.

To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com or write to us at hello@cmabbio.com. We look forward to hearing from you.
phone +41 61 564 03 57
email hello@cmabbio.com
web www.cmabbio.com
email Teichgässlein 9, 4058 Basel, Switzerland
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 
News and Press Releases

Finalists revealed for CPhI Worldwide’s eagerly anticipated 2019 Awards

London, 17th October 2019: CPhI Worldwide announces the finalists for the CPhI Pharma Awards. The shortlist spans 13 different categories across the full spectrum of the pharmaceutical supply chain, including Formulation, Packaging and Lifetime Achievement Awards.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement